<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4941">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03042611</url>
  </required_header>
  <id_info>
    <org_study_id>LSK-AM301</org_study_id>
    <nct_id>NCT03042611</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Trial of Apatinib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Patients With Gastric Cancer</brief_title>
  <acronym>ANGEL</acronym>
  <official_title>A Prospective, Randomized, Double-Blinded, Placebo-Controlled, Multinational, Multicenter, Parallel-group, Phase III Study to Evaluate the Efficacy and Safety of Apatinib Plus Best Supportive Care (BSC) Compared to Placebo Plus BSC in Patients With Advanced or Metastatic Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LSK BioPartners Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LSK BioPartners Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the clinical benefit and safety of Apatinib plus
      Best Supportive Care in comparison to Placebo plus Best Supportive Care in patients with
      advanced or metastatic gastric cancer
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 24, 2017</start_date>
  <completion_date type="Anticipated">December 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator</masking>
    <masking_description>Double Blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Time from randomization until death, assessed up to approximately 18 months</time_frame>
    <description>Subjects alive or lost to follow-up at the end of study are censored</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>Time from randomization to either radiologic disease progression or death, assessed up to approximately 18 months</time_frame>
    <description>Subjects alive and free of progression at the end of study are censored</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>Approximately every 8 weeks from baseline through End of Treatment (EOT) and study completion, assessed up to approximately 18 months</time_frame>
    <description>Percentage of subjects with a Best Overall Response of Complete Response (CR) or Partial Response (PR). RECIST Guideline version 1.1 will be used to assess tumor response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate</measure>
    <time_frame>Approximately every 8 weeks from baseline through EOT and study completion, assessed up to approximately 18 months</time_frame>
    <description>Proportion of subjects with a Best Overall Response of complete response, partial response, or stable disease. RECIST Guideline Version 1.1 will be used to assess tumor response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Live Assessed by EORTC QLQ-C30</measure>
    <time_frame>Every 28 days from baseline through EOT and study completion, assessed up to approximately 18 months</time_frame>
    <description>Global health status/quality of life score according to European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Live Assessed by EORTC QLQ-STO22</measure>
    <time_frame>Every 28 days from baseline through EOT and study completion, assessed up to approximately 18 months</time_frame>
    <description>Global health status/quality of life score according to European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-EORTC QLQ-STO22</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Assessed by EQ-5D-5L</measure>
    <time_frame>Every 28 days from baseline through EOT and study completion, assessed up to approximately 18 months</time_frame>
    <description>Each dimension response according to EuroQol 5-Dimension 5-Level (EQ-5D-5L) Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>Screening through 28 days after last dose of study drug and study completion, assessed up to approximately 18 months</time_frame>
    <description>Assessed by: Adverse events, laboratory tests, vital signs, physical examination, 12-lead ECG, and ECOG performance status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor Pharmacodynamic Markers</measure>
    <time_frame>Every 28 days from baseline through EOT and study completion, assessed up to approximately 18 months</time_frame>
    <description>Vascular Endothelial Growth Factor (VEGF), sVEGFR-1, sVEGFR2 and sVEGFR3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of Apatinib as assessed by Maximum Plasma Concentration [Cmax]</measure>
    <time_frame>Cycle 1 Day 1 and Day 15 assessed within approximately 9 months after last patient enrolled</time_frame>
    <description>Maximum Plasma Concentration [Cmax]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of Apatinib as assessed by Trough level of Plasma Concentrations</measure>
    <time_frame>Every 28 days from baseline up to EOT through study completion, assessed up to approximately 18 months</time_frame>
    <description>Trough Level Plasma Concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of Apatinib as assessed by Area Under the Curve [AUC]</measure>
    <time_frame>Every 28 days from baseline up to EOT through study completion and Cycle 1 Day 15, assessed up to approximately 18 months</time_frame>
    <description>Area under the plasma concentration vs time curve (AUC)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">459</enrollment>
  <condition>Gastric Cancer</condition>
  <condition>Gastric Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Apatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib</intervention_name>
    <description>Daily oral dose of Apatinib plus Best Supportive Care defined as palliative non-cancer therapy at the Investigator's discretion</description>
    <arm_group_label>Apatinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Daily oral dose of Placebo with Best Supportive Care defined as palliative non-cancer therapy at the Investigator's discretion</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female ≥ 18 years of age.

          2. Documented primary diagnosis of histologic- or cytologic-confirmed adenocarcinoma of
             the stomach or gastroesophageal junction.

          3. Locally advanced unresectable or metastatic disease that has progressed since last
             treatment.

          4. One or more measurable or nonmeasurable evaluable lesions per RECIST 1.1.

          5. Failure or intolerance to at least two prior lines of standard chemotherapies with
             each containing one or more of the following agents:

               -  fluoropyrimidine (IV 5-FU capecitabine, or S-1),

               -  platinum (cisplatin or oxaliplatin),

               -  taxanes (paclitaxel or docetaxel) or epirubicin,

               -  irinotecan,

               -  trastuzumab in case of HER2-positive

               -  ramucirumab

          6. Disease progression within 6 months after the last treatment.

          7. Adequate bone-marrow, renal and liver function.

          8. Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1.

          9. Expected survival of ≥ 12 weeks, in the opinion of the investigator.

         10. Ability to swallow the investigational product tablets.

         11. Female patients with negative pregnancy test at Screening and use of acceptable
             method of birth control for study duration, unless surgically sterile or
             postmenopausal for at least 1 year prior to Screening.

         12. Ability and willingness to comply with the study protocol for the duration of the
             study and with follow-up procedures.

        Exclusion Criteria:

          1. Malignancies other than adenocarcinoma of the stomach or gastroesophageal junction
             (including hematologic malignancies) within 3 years.

          2. CNS metastases as shown by radiology records or clinical evidence of symptomatic CNS
             involvement in the last 3 months prior to randomization.

          3. Cytotoxic chemotherapy, surgery, immunotherapy, radiotherapy or other targeted
             therapies within 4 weeks (6 weeks in cases of ramucirumab, mitomycin C, nitrosourea,
             lomustine; 2 weeks in case of biopsy) prior to randomization (Adjuvant radiotherapy
             given to local area for non-curative symptom relief is allowed until 2 weeks before
             randomization.).

          4. Therapy with clinically significant systemic anticoagulant or antithrombotic agents
             within 7 days prior to randomization that may prevent blood clotting and, in the
             investigator's opinion, could place the subject at risk.

          5. Patients who had therapeutic paracentesis of ascites (&gt; 1L) within the 3 months prior
             to starting study treatment or who, in the opinion of the investigator, will likely
             need therapeutic paracentesis of ascites (&gt; 1L) within 3 months of starting study
             treatment.

          6. Previous treatment with Apatinib.

          7. Known hypersensitivity to Apatinib or components of the formulation.

          8. Concomitant treatment with strong inhibitors or inducers of CYP3A4, CYP2C9 and
             CYP2C19.

          9. Active bacterial infections.

         10. Substance abuse or medical, psychological, or social conditions that may interfere
             with the patient's participation in the study or evaluation of the study results.

         11. Participation in any other clinical trial within 4 weeks prior to randomization.

         12. Pregnant or breast-feeding women.

         13. History of drug or alcohol abuse within past 5 years.

         14. Medical or psychiatric illnesses that, in the investigator's opinion, may impact the
             safety of the subject or the objectives of the study.

         15. History of uncontrolled hypertension (Blood pressure ≥ _140/90 mmHg and change in
             antihypertensive medication within 7 days prior to randomization) that is not well
             managed by medication and the risk of which may be precipitated by a VEGF inhibitor
             therapy.

         16. Known history of symptomatic congestive heart failure (New York Heart Association
             III-IV), symptomatic or poorly controlled cardiac arrhythmia, complete left bundle
             branch block, bifascicular block, or any clinically significant ST segment and/or
             T-wave abnormalities, QTcF &gt; 450 msec prior to randomization.

         17. Prior major surgery or fracture within 3 weeks prior to randomization or presence of
             any non-healing wound.

         18. History of bleeding diathesis or clinically significant bleeding within 14 days prior
             to randomization.

         19. History of clinically significant thrombosis within the past 3 months prior to
             randomization that, in the investigator's opinion, may place the patient at risk of
             side effects from anti-angiogenesis products.

         20. History of gastrointestinal bleeding, gastric stress ulcerations, or peptic ulcer
             disease within the past 3 months prior to randomization that, in the investigator's
             opinion, may place the patient at risk of side effects from anti-angiogenesis
             products.

         21. Myocardial infarction or unstable angina pectoris within 6 months prior to
             randomization.

         22. History of severe adverse events, in the investigator's opinion, related to
             ramucirumab.

         23. History of other significant cardiovascular diseases or vascular diseases within the
             last 6 months prior to randomization that, in the investigator's opinion, may pose a
             risk to the patient on VEGF inhibitor therapy.

         24. History of clinically significant glomerulonephritis, biopsy-proven
             tubulointerstitial nephritis, crystal nephropathy, or other renal insufficiencies.

         25. Gastrointestinal malabsorption, or any other condition that in the opinion of the
             investigator might affect the absorption of the study drug.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott Houston</last_name>
    <role>Study Director</role>
    <affiliation>LSK BioPartners Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rahul Gowda (South Korea)</last_name>
    <phone>+82-2-546-1008</phone>
    <email>AM301Study@lskglobal.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yumi.Mizuma@mpi-cro.jp (Japan); llu.fan@statplus.com (Taiwan), Statplus-Taiwan</last_name>
    <phone>MPI-JP, Chiltern-EU/US</phone>
    <email>Vyacheslav.Lyskov@chiltern.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hyogo Cancer Center</name>
      <address>
        <city>Hyogo</city>
        <state>Akasi-city</state>
        <zip>673-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiba Cancer Center</name>
      <address>
        <city>Chiba</city>
        <state>Chiba City</state>
        <zip>260-8717</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital</name>
      <address>
        <city>Tokyo</city>
        <state>Chuo-ku</state>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kyushu University Hospital</name>
      <address>
        <city>Fukuoka</city>
        <state>Higashi-ku</state>
        <zip>812-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East</name>
      <address>
        <city>Chiba</city>
        <state>Kashiwa</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Marianna University Hospital</name>
      <address>
        <city>Kanagawa</city>
        <state>Kawasaki-shi</state>
        <zip>216-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Saitama Cancer Center</name>
      <address>
        <city>Saitama</city>
        <state>Kitaadachi-gun</state>
        <zip>362-0806</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Japan Community Health Care Organization Kyushu Hospital</name>
      <address>
        <city>Fukuoka</city>
        <state>Kitakyushu-shi</state>
        <zip>806-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Cancer Institute Hospital of Japanese Foundation For Cancer Research</name>
      <address>
        <city>Tokyo</city>
        <state>Koto-ku</state>
        <zip>135-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shikoku Cancer Center</name>
      <address>
        <city>Ehime</city>
        <state>Matsuyama</state>
        <zip>791-0280</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Saku Central Hospital Advanced Care Center</name>
      <address>
        <city>Nagano</city>
        <state>Saku-shi</state>
        <zip>385-0051</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hokkaido University Hospital</name>
      <address>
        <city>Hokkaido</city>
        <state>Sapporo</state>
        <zip>060-8648</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Keio University Hospital</name>
      <address>
        <city>Tokyo</city>
        <state>Shinjuku-ku</state>
        <zip>160-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Osaka University Hospital</name>
      <address>
        <city>Osaka</city>
        <state>Suita</state>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aichi Cancer Center Hospital</name>
      <address>
        <city>Nagoya</city>
        <zip>464-8681</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Inje University Haeundae Paik Hospital</name>
      <address>
        <city>Haeundae-gu</city>
        <state>Busan</state>
        <zip>48108</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dong-A University Hospital</name>
      <address>
        <city>Seo-gu</city>
        <state>Busan</state>
        <zip>49201</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pusan National University Hospital</name>
      <address>
        <city>Seo-gu</city>
        <state>Busan</state>
        <zip>49241</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chungbuk National University Medical Center</name>
      <address>
        <city>Seowon-gu</city>
        <state>Chungcheongbuk-do</state>
        <zip>41404</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Medical Center</name>
      <address>
        <city>Buk-gu</city>
        <state>Daegu</state>
        <zip>41404</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Keimyung University Dongsan Medical Center</name>
      <address>
        <city>Jung-gu</city>
        <state>Daegu</state>
        <zip>41931</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yeungnam University Medical Center</name>
      <address>
        <city>Nam-gu</city>
        <state>Daegu</state>
        <zip>42415</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chungnam National University Hospital</name>
      <address>
        <city>Jung-gu</city>
        <state>Daejeon</state>
        <zip>35015</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hallym University Sacred Heart Hospital</name>
      <address>
        <city>Anyang-si</city>
        <state>Gyeonggi-do</state>
        <zip>14069</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Bundang-gu</city>
        <state>Gyeonggi-do</state>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Goyang-si</city>
        <state>Gyeonggi-do</state>
        <zip>10408</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Suwon-si</city>
        <state>Gyonggi-do</state>
        <zip>16499</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gachon University Gil Medical Center</name>
      <address>
        <city>Namdong-gu</city>
        <state>Incheon</state>
        <zip>21555</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chonbuk National University Hospital</name>
      <address>
        <city>Jeonju-si</city>
        <state>Jeollabuk-do</state>
        <zip>54907</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Veterans Health Service (VHS) Medical Center</name>
      <address>
        <city>Gangdong-gu</city>
        <state>Seoul</state>
        <zip>05368</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gangnam Severance Hospital</name>
      <address>
        <city>Gangnam-gu</city>
        <state>Seoul</state>
        <zip>06273</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Gangnam-gu</city>
        <state>Seoul</state>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Guro-gu</city>
        <state>Seoul</state>
        <zip>08308</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Severence Hospital, Yonsei University Health System</name>
      <address>
        <city>Seodaemun-gu</city>
        <state>Seoul</state>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seongbuk-gu</city>
        <state>Seoul</state>
        <zip>02841</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ASAN Medical Center</name>
      <address>
        <city>Songpagu</city>
        <state>Seoul</state>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ulsan University Hospital</name>
      <address>
        <city>Dong-gu</city>
        <state>Ulsan</state>
        <zip>44033</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <state>Beitou Dist</state>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital - Linko Branch</name>
      <address>
        <city>Taoyuan</city>
        <state>Kuei Shan Hsiang</state>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chi Mei Medical Center - LiouYing Branch</name>
      <address>
        <city>Tainan</city>
        <state>Liuying DIst</state>
        <zip>736</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital - Kaohsiung Branch</name>
      <address>
        <city>Kaohsiung</city>
        <state>Niaosong Dist</state>
        <zip>83301</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Medical University Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <state>Sanmin Dist</state>
        <zip>80708</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <state>Taichung City</state>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>National CHeng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <state>Tainan City</state>
        <zip>70403</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <state>Zhongzheng Dist</state>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 27, 2017</lastchanged_date>
  <firstreceived_date>January 24, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gastric Cancer</keyword>
  <keyword>Gastric Adenocarcinoma</keyword>
  <keyword>Gastro-esophageal Cancer</keyword>
  <keyword>Gastro-esophageal junction Cancer</keyword>
  <keyword>Stomach Cancer</keyword>
  <keyword>Tumor</keyword>
  <keyword>Oncology</keyword>
  <keyword>Antiangiogenesis</keyword>
  <keyword>Metastatic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
